In the last trading session, 10.83 million Akebia Therapeutics Inc (NASDAQ:AKBA) shares changed hands as the company’s beta touched 0.85. With the company’s per share price at $3.92 changed hands at $0.09 or 2.35% during last session, the market valuation stood at $1.03B. AKBA’s last price was a discount, traded about -4.08% off its 52-week high of $4.08. The share price had its 52-week low at $0.80, which suggests the last value was 79.59% up since then.
Analysts gave the Akebia Therapeutics Inc (AKBA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AKBA as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Instantly AKBA was in green as seen at the end of in last trading. With action 14.62%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 106.32%, with the 5-day performance at 14.62% in the green. However, in the 30-day time frame, Akebia Therapeutics Inc (NASDAQ:AKBA) is 53.73% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need an upside of 39.69% from its current market value. According to analyst projections, AKBA’s forecast low is 6 with 7 as the target high. To hit the forecast high, the stock’s price needs a -78.57% plunge from its current level, while the stock would need to soar -53.06% for it to hit the projected low.
Akebia Therapeutics Inc (AKBA) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 32.58%. The 2025 estimates are for Akebia Therapeutics Inc earnings to increase by 80.61%.
Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.4235% or 9.28 million shares worth $9.46 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. With 7.84 shares estimated at $30.74 million under it, the former controlled 2.99% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.06% of the shares, roughly 5.4 shares worth around $21.19 million.
